Shares of Emcure Pharmaceuticals declined by more than 2% on Friday, with more than 1 lakh shares changing hands—sharply higher than the two-week average volume of 4,396 shares. The stock witnessed selling pressure amid reports that American private investment firm Bain Capital was looking to sell an equity stake worth ₹551 crore via a block deal.

Bain Capital-affiliated entity BC Investments IV was reportedly planning to offload a 2.4% stake, or 4.5 million shares, in the company at a floor price of ₹1,279.80 apiece, a marginal discount against its previous closing of ₹1,280.30 on the BSE. 

As of March 2025, BC Investments IV owned an 8.68% stake, or 16.4 million shares, in Emcure Pharma, while Shark Tank judge Namita Vikas Thapar held 5.07 million shares, or a 2.68% stake, in the pharmaceutical company. The promoter groups owned a majority stake of 77.9% in the firm.

In response to reports on the block deal, Emcure Pharma shares declined as much as 2.5% to ₹1,247.65 on the BSE. The pharma stock opened at ₹1,265.15, down 1.2% against the previous closing price. At the time of reporting, the midcap stock was down 1.9% at ₹1,256, with a market capitalisation of ₹23,800 crore.

Emcure Pharmaceuticals made its market debut on July 10, 2024. The shares of the Pune-based company have risen 27% against its IPO price of ₹1,008, while it touched its record high level of ₹1,577.50 on September 18, 2024. The counter slipped to its lowest of ₹890 on April 7.

For the fourth quarter ended March 2025, Emcure Pharmaceuticals reported a 63% year-on-year (YoY) jump in consolidated net profit to ₹197 crore, while revenue from operations stood at ₹2,116 crore, up 19.5% YoY, driven by performance across both its domestic and international businesses. On the operating front, Ebitda grew 25.2% YoY to ₹390 crore, while the margin increased to 18.4% from 17.6% in the corresponding period last year.

Last month, Emcure Pharma received its board's approval to sign a deal with minority shareholders of Zuventus Healthcare, one of its subsidiaries, to acquire their shareholding. Following the completion of this transaction, expected to close in Q2FY26, Zuventus will become a wholly owned subsidiary of Emcure.

“The domestic market remains a strategic priority for Emcure. This transaction will enable full financial consolidation of Zuventus and drive long-term value creation for Emcure, through alignment across its domestic business and unlock synergies,” it said in a BSE filing on June 21.

(DISCLAIMER: The views and opinions expressed by investment experts on fortuneindia.com are either their own or of their organisations, but not necessarily that of fortuneindia.com and its editorial team. Readers are advised to consult certified experts before taking investment decisions.)